DI PERRI, Giovanni
DI PERRI, Giovanni
SCIENZE MEDICHE
2019 novel coronavirus (2019-nCoV) outbreak: A new challenge
2020-01-01 Lupia T.; Scabini S.; Mornese Pinna S.; Di Perri G.; De Rosa F.G.; Corcione S.
[Relapsing infection of cranial prosthesis sustained by Enterobacter cloacae and methicillin-resistant Staphylococcus aureus]
2008-01-01 Garazzino S; De Rosa FG; Bargiacchi O; Di Perri G.
A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?
2014-01-01 Baietto, L; Corcione, S; Pacini, G; Di Perri, G; D'Avolio, A; De Rosa, FG
A case of dengue type 3 virus infection imported from Africa to Italy, October 2009
2010-01-01 Nisii C; Carletti F; Castilletti C; Bordi L; Meschi S; Selleri M; Chiappini R; Travaglini D; Antonini M; Castorina S; Lauria FN; Narciso P; Gentile M; Martini L; Di Perri G; Audagnotto S; Biselli R; Lastilla M; Di Caro A; Capobianchi M; Ippolito G.
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop
2014-01-01 A. De Nicolò; A. Ciancio; L. Boglione; A. Mohamed Abdi; A. Smedile; G.P. Caviglia; G. DI Perri; M. Rizzetto; A. D'Avolio
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load
2010-01-01 Calcagno A; Milia MG; D'Avolio A; Ndayishimiyae P; Dusabimana P; Bonora S; Cusato J; Simiele M; Rostagno R; Siccardi M; Audagnotto S; Ghisetti V; Di Perri G.
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.
2011-01-01 A. D'Avolio;M. Simiele;M. Siccardi;L. Baietto;M. Sciandra;V. Oddone;F. R. Stefani;S. Agati;J. Cusato;S. Bonora;G. Di Perri
A LC-MS method to quantify tenofovir urinary concentrations in treated patients
2015-01-01 Simiele, Marco; Carcieri, Chiara; DE NICOLO', Amedeo; Ariaudo, Alessandra; Sciandra, Mauro; Calcagno, Andrea; Bonora, Stefano; DI PERRI, Giovanni; D'Avolio, Antonio
A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients
2008-01-01 Antonio D'Avolio; Mauro Sciandra; Marco Siccardi; Lorena Baietto; Daniel Gonzalez de; Stefano Bonora; Giovanni Di Perri
A new HPLC method to measure plasma levels of enfuvirtide (ENF or T-20)
2004-01-01 D'Avolio A.; Sciandra M.; Bonora S.; Ibanez A.; Marucco D.; Di Perri G.
A new UPLC-MS-MS method to quantify first line antituberculosis agents in plasma spotted on dried sample spots device (DSSD)
2015-01-01 L. Baietto; V. Poretti; K. Baruffi; G. Di Perri; A. D'Avolio
A new validated Solid Phase Extraction (SPE)-HPLC method to measure plasma concentrations of tenofovir
2004-01-01 D'Avolio A.; Sciandra M.; Bonora S.; Boffito M.; Canta F.; De Requena D.; Di Perri G.
A pharmacogenetic study in HIV-infected patients treated with ritonavir: hematological and cardiovascular disease risk analysis
2021-01-01 Cusato, J; Calcagno, A; Antonucci, M; Marinaro, L; Avataneo, V; De Nicolò, Amedeo; Bonora, S; Di Perri, G; D'avolio, A
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients.
2008-01-01 Bonora S; D'Avolio A; Tettoni C; Siccardi M; Gonzalez de Requena D; Baietto L; Cometto C; Sciandra M; Trentini L; Di Perri G.
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance
2009-01-01 Schipani A; Siccardi M; D'Avolio A; Baietto L; Calcagno A; Tettoni C; Bonora S; Davis G; Khoo S; Back DJ; Di Perri G; Owen A
A Population Pharmacokinetic Model Illustrates an Association Between a Pregnane-X-Receptor (PXR) Polymorphism and Boosted Atazanavir Clearance
2010-01-01 Schipani A; Siccardi M; Boffito M; D’Avolio A; Bonora S; Davies G; Khoo S; Back D; Di Perri G; Owen A
A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4
2017-01-01 Boglione, Lucio; Ruggiero, Tina; De Nicolò, Amedeo; D'Avolio, Antonio; Di Perri, Giovanni
A review of the safety and tolerability profile of the next-generation NNRTI etravirine.
2010-01-01 Grinsztejn B; Di Perri G; Towner W; Woodfall B; De Smedt G; Peeters M.
A short course of pegylated interferon-alpha in acute HCV hepatitis
2007-01-01 CALLERI G; CARITI G; GAIOTTINO F; DE ROSA FG; BARGIACCHI O; AUDAGNOTTO S; QUAGLIA S; DE BLASI T; ROMANO P; TRAVERSO A; LEO G; CARBONE R; DEL MASTRO B; TINELLI M; CARAMELLO P; DI PERRI G
A Simple and Fast Method for Quantification of Ertapenem using Meropenem as Internal Standard in Human Plasma in a Clinical Setting
2008-01-01 D'AVOLIO A; BAIETTO L; DE ROSA FG; GARAZZINO S; SCIANDRA M; SICCARDI M; BONORA S; DI PERRI G
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge | 2020 | Lupia T.; Scabini S.; Mornese Pinna S.; Di Perri G.; De Rosa F.G.; Corcione S. | |
| [Relapsing infection of cranial prosthesis sustained by Enterobacter cloacae and methicillin-resistant Staphylococcus aureus] | 2008 | Garazzino S; De Rosa FG; Bargiacchi O; Di Perri G. | |
| A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics? | 2014 | Baietto, L; Corcione, S; Pacini, G; Di Perri, G; D'Avolio, A; De Rosa, FG | |
| A case of dengue type 3 virus infection imported from Africa to Italy, October 2009 | 2010 | Nisii C; Carletti F; Castilletti C; Bordi L; Meschi S; Selleri M; Chiappini R; Travaglini D; Antonini M; Castorina S; Lauria FN; Narciso P; Gentile M; Martini L; Di Perri G; Audagnotto S; Biselli R; Lastilla M; Di Caro A; Capobianchi M; Ippolito G. | |
| A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop | 2014 | A. De Nicolò; A. Ciancio; L. Boglione; A. Mohamed Abdi; A. Smedile; G.P. Caviglia; G. DI Perri; M. Rizzetto; A. D'Avolio | |
| A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load | 2010 | Calcagno A; Milia MG; D'Avolio A; Ndayishimiyae P; Dusabimana P; Bonora S; Cusato J; Simiele M; Rostagno R; Siccardi M; Audagnotto S; Ghisetti V; Di Perri G. | |
| A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. | 2011 | A. D'Avolio;M. Simiele;M. Siccardi;L. Baietto;M. Sciandra;V. Oddone;F. R. Stefani;S. Agati;J. Cusato;S. Bonora;G. Di Perri | |
| A LC-MS method to quantify tenofovir urinary concentrations in treated patients | 2015 | Simiele, Marco; Carcieri, Chiara; DE NICOLO', Amedeo; Ariaudo, Alessandra; Sciandra, Mauro; Calcagno, Andrea; Bonora, Stefano; DI PERRI, Giovanni; D'Avolio, Antonio | |
| A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients | 2008 | Antonio D'Avolio; Mauro Sciandra; Marco Siccardi; Lorena Baietto; Daniel Gonzalez de; Stefano Bonora; Giovanni Di Perri | |
| A new HPLC method to measure plasma levels of enfuvirtide (ENF or T-20) | 2004 | D'Avolio A.; Sciandra M.; Bonora S.; Ibanez A.; Marucco D.; Di Perri G. | |
| A new UPLC-MS-MS method to quantify first line antituberculosis agents in plasma spotted on dried sample spots device (DSSD) | 2015 | L. Baietto; V. Poretti; K. Baruffi; G. Di Perri; A. D'Avolio | |
| A new validated Solid Phase Extraction (SPE)-HPLC method to measure plasma concentrations of tenofovir | 2004 | D'Avolio A.; Sciandra M.; Bonora S.; Boffito M.; Canta F.; De Requena D.; Di Perri G. | |
| A pharmacogenetic study in HIV-infected patients treated with ritonavir: hematological and cardiovascular disease risk analysis | 2021 | Cusato, J; Calcagno, A; Antonucci, M; Marinaro, L; Avataneo, V; De Nicolò, Amedeo; Bonora, S; Di Perri, G; D'avolio, A | |
| A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. | 2008 | Bonora S; D'Avolio A; Tettoni C; Siccardi M; Gonzalez de Requena D; Baietto L; Cometto C; Sciandra M; Trentini L; Di Perri G. | |
| A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance | 2009 | Schipani A; Siccardi M; D'Avolio A; Baietto L; Calcagno A; Tettoni C; Bonora S; Davis G; Khoo S; Back DJ; Di Perri G; Owen A | |
| A Population Pharmacokinetic Model Illustrates an Association Between a Pregnane-X-Receptor (PXR) Polymorphism and Boosted Atazanavir Clearance | 2010 | Schipani A; Siccardi M; Boffito M; D’Avolio A; Bonora S; Davies G; Khoo S; Back D; Di Perri G; Owen A | |
| A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4 | 2017 | Boglione, Lucio; Ruggiero, Tina; De Nicolò, Amedeo; D'Avolio, Antonio; Di Perri, Giovanni | |
| A review of the safety and tolerability profile of the next-generation NNRTI etravirine. | 2010 | Grinsztejn B; Di Perri G; Towner W; Woodfall B; De Smedt G; Peeters M. | |
| A short course of pegylated interferon-alpha in acute HCV hepatitis | 2007 | CALLERI G; CARITI G; GAIOTTINO F; DE ROSA FG; BARGIACCHI O; AUDAGNOTTO S; QUAGLIA S; DE BLASI T; ROMANO P; TRAVERSO A; LEO G; CARBONE R; DEL MASTRO B; TINELLI M; CARAMELLO P; DI PERRI G | |
| A Simple and Fast Method for Quantification of Ertapenem using Meropenem as Internal Standard in Human Plasma in a Clinical Setting | 2008 | D'AVOLIO A; BAIETTO L; DE ROSA FG; GARAZZINO S; SCIANDRA M; SICCARDI M; BONORA S; DI PERRI G |